Search Within

Katherine Marie Bell-McGuinn

Formats
  1. Meeting Abstract (32)
  2. Journal Article (27)
  3. Book Section (1)
Groups
  1. Gynecology Disease Management Team (35)
  2. Department of Medicine (34)
  3. Solid Tumor Oncology Division (34)
  4. GDMT, Medicine (32)
  5. Gynecologic Medicine Service (32)
  6. Surgery (9)

More Groups

People
  1. Carol Aghajanian (29)
  2. Jason Konner (13)
  3. Paul Sabbatini (11)
  4. William Tew (10)
  5. Martee Hensley (9)
  6. David Spriggs (8)

More People

Years
  1. 2021 (1)
  2. 2020 (5)
  3. 2019 (2)
  4. 2018 (4)
  5. 2017 (4)
  6. 2016 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Gynecologic Oncology (15)
  3. Clinical Cancer Research (7)
  4. Cancer Research (5)
  5. Annals of Oncology (4)
  6. Diagnostic Pathology of Ovarian Tumors (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. Elsevier B.V. (15)
  3. American Association for Cancer Research (12)
  4. Oxford University Press (4)
  5. Elsevier Science, Inc. (2)
  6. Springer (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: A phase I study
    Journal Article

    Konner, J. A.; Bell-Mcguinn, K. M.; Sabbatini, P.; Hensley, M. L.; Tew, W. P.; Pandit-Taskar, N.; Vander Els, N.; Phillips, M. D.; Schweizer, C.; Weil, S. C.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial
    Journal Article

    Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-Mcguinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; more...
    Lancet (2010)

    Fulltext@MSK | Save
  • A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer
    Meeting Abstract

    Konner, J. A.; Grabon, D.; Pezzulli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Bell-McGuinn, K.; Tew, W.; Spriggs, D.; Aghajanian, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
    Meeting Abstract

    Audeh, M. W.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Carmichael, J.; Tutt, A.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer
    Journal Article

    Zivanovic, O.; Sima, C. S.; Iasonos, A.; Bell-Mcguinn, K. M.; Sabbatini, P. J.; Leitao, M. M.; Levine, D. A.; Gardner, G. J.; Barakat, R. R.; Chi, D. S.
    Gynecologic Oncology (2009)

    Fulltext@MSK | Save
  • Survival benefit for BRCA-associated epithelial ovarian cancer (OC) is not explained by primary platinum sensitivity alone
    Meeting Abstract

    Konner, J. A.; Gallagher, D. J.; Bell-McGuinn, K. M.; Hansen, J.; Kosarin, K.; Aghajanian, C. A.; Offit, K.; Barakat, R. R.; Spriggs, D. R.; Kauff, N. D.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase I study of MORAb-003, a humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer
    Meeting Abstract

    Bell-McGuinn, K. M.; Konner, J. A.; Pandit-Taskar, N.; Larson, S. M.; Gerst, S. R.; VanderEls, N.; Old, L.; Weil, S.; Phillips, M.; Aghajanian, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A phase 2, single-arm study of volociximab (an anti-a5 beta 1 integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer
    Meeting Abstract

    Matthews, C. M.; Ho, S. N.; Barve, M.; Bell-Mcguinn, K. M.; Gilbert, L.; Penson, R. T.; Lengyel, E.; Weymer, S.; Gilder, K.; Schilder, R. J.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer
    Journal Article

    Bell-Mcguinn, K. M.; Garfall, A. L.; Bogyo, M.; Hanahan, D.; Joyce, J. A.
    Cancer Research (2007)

    Fulltext@MSK | Save
  • Cysteine cathepsin inhibition in combination with a maximum-tolerated dose and metronomic dose "chemo-switch" regimen leads to tumor regression and an overall survival benefit in a marine model of cancer
    Meeting Abstract

    Bell-Mcguinn, K. M.; Bogyo, M.; Hanahan, D.; Joyce, J.
    Cancer Research (2006)

    Fulltext@MSK | Save